GlobeNewswire: Interpace Biosciences, Inc. Contains the last 10 of 129 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:05:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842198/0/en/Interpace-Biosciences-Announces-Preliminary-Full-year-and-Fourth-Quarter-2023-Financial-and-Business-Results.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results2024-03-07T13:00:00Z<![CDATA[PARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year ending December 31, 2023.]]>https://www.globenewswire.com/news-release/2023/11/08/2776634/0/en/Interpace-Biosciences-Announces-Record-Third-Quarter-2023-Financial-and-Business-Results.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results2023-11-08T20:29:00Z<![CDATA[PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2023 and provided a business and financial update.]]>https://www.globenewswire.com/news-release/2023/08/09/2721963/0/en/Interpace-Biosciences-Announces-Record-Second-Quarter-2023-Financial-and-Business-Results.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results2023-08-09T16:30:00Z<![CDATA[PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 and provided a business and financial update.]]>https://www.globenewswire.com/news-release/2023/07/10/2702163/0/en/Interpace-Biosciences-Releases-Preliminary-Record-Second-Quarter-2023-Business-Results-Updates-Status-of-PancraGEN-Reimbursement.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement2023-07-10T19:59:00Z<![CDATA[PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending June 30, 2023, and provided an update on recent activities. Final Q2 financial results are expected to be released no later than August 11, 2023.]]>https://www.globenewswire.com/news-release/2023/06/05/2682365/0/en/Interpace-Expects-to-Stop-Offering-PancraGEN-Test-Due-to-CMS-Decision-to-End-Reimbursement-as-of-July-17-2023.html?f=22&fvtc=4&fvtv=49577Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 20232023-06-05T20:05:00Z<![CDATA[PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issued the final Local Coverage Determination (LCD) of Genetic Testing for Oncology (L39365) which establishes non-coverage for the Company’s widely used PancraGEN® test effective July 17, 2023. Commercially available in its current form since 2013, PancraGEN is a DNA-based molecular diagnostic test that uniquely assesses the risk of pancreatic cancer posed by pancreatic cysts and is used to rule-in and rule-out (risk-stratify) the disease. The important information provided by PancraGEN helps support the differential diagnosis of pancreatic cancer by integrating the results of first-line tests and procedures with molecular test results. This insight aids physicians in their diagnosis of pancreatic cancer and helps inform the optimal management of patients, including through the reduction of unnecessary surgeries.]]>https://www.globenewswire.com/news-release/2023/05/12/2668161/0/en/Interpace-Biosciences-Announces-Record-First-Quarter-2023-Financial-and-Business-Results.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results2023-05-12T20:05:00Z<![CDATA[PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update.]]>https://www.globenewswire.com/news-release/2023/03/27/2635230/0/en/Interpace-Biosciences-Announces-Full-Year-and-Fourth-Quarter-2022-Financial-and-Business-Results.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results2023-03-27T20:05:00Z<![CDATA[PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2022 and provided a business and financial update.]]>https://www.globenewswire.com/news-release/2022/11/14/2555528/0/en/Interpace-Biosciences-Announces-Third-Quarter-2022-Financial-and-Business-Results-Sale-of-Pharma-Significantly-Improves-Liquidity-Resulting-in-Removal-of-Going-Concern.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern2022-11-14T21:41:35Z<![CDATA[PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2022 and provided a business and financial update.]]>https://www.globenewswire.com/news-release/2022/10/20/2538851/0/en/Interpace-Biosciences-Announces-New-Real-world-Data-Presented-at-the-American-Thyroid-Association-2022-Annual-Meeting.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting2022-10-20T20:28:36Z<![CDATA[PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new real-world clinical utility data for their ThyGeNEXT® + ThyraMIR®v2 combination test platform to assess the malignancy risk of indeterminate thyroid nodules (ITN). The findings are from an independent study and were shared today in a highlighted poster presentation during the American Thyroid Association (ATA) 2022 Annual Meeting (Poster #119). The poster can also be viewed at www.thyroiddx.com/poster.]]>https://www.globenewswire.com/news-release/2022/09/01/2508979/0/en/Interpace-Biosciences-Announces-New-Clinical-Validation-Data-Diagnostic-Accuracy-Significantly-Improved.html?f=22&fvtc=4&fvtv=49577Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved2022-09-01T21:18:00Z<![CDATA[PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel (ThyGeNEXT®) and a microRNA (miRNA) risk classifier. The new data demonstrates that the addition of miRNA pairwise expression profiling (ThyraMIR®v2) provides clinically and statistically superior risk stratification of indeterminate thyroid nodules (ITN) beyond that of the algorithmic classification analysis provided by the original ThyraMIR® assay.]]>